サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1793315

治療のためのRNAiの世界市場：市場レポート、競合分析、地域別機会 (2025年～2031年)

Global RNAi for Therapeutic Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031

出版日
発行
QYResearch
ページ情報
英文 92 Pages
納期
2～3営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.45円
治療のためのRNAiの世界市場：市場レポート、競合分析、地域別機会 (2025年～2031年)
出版日: 2025年08月19日
発行: QYResearch
ページ情報: 英文 92 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、治療のためのRNAi (RNAi for Therapeutic) 市場について調査しており、市場規模や動向・需要の予測、成長要因および課題の分析、タイプ・用途・企業・地域別の内訳、競合情勢、主要企業のプロファイルなどの情報を提供しています。

目次

第1章 レポート概要

  • 調査範囲
  • 市場：タイプ別
    • 世界のタイプ別市場成長: 2020 VS 2024 VS 2031
    • siRNA
    • miRNA
    • shRNA
  • 市場：用途別
    • 世界の用途別市場シェア: 2020 VS 2024 VS 2031
    • Cancer
    • Cardiovascular
    • HBV
    • Others
  • 前提条件と制限
  • 調査目的
  • 対象期間

第2章 世界の市場成長トレンド

  • 世界の治療のためのRNAiの市場展望 (2020-2031)
  • 世界の市場規模：地域別: 2020 VS 2024 VS 2031
  • 世界の治療のためのRNAiの収益市場シェア 地域別 (2020-2025)
  • 世界の治療のためのRNAiの収益予測：地域別 (2026-2031)
  • 主要地域と新興市場分析
    • 北米の治療のためのRNAi 市場規模および予測 (2020-2031)
    • 欧州の治療のためのRNAi 市場規模および予測 (2020-2031)
    • 中国の治療のためのRNAi 市場規模および予測 (2020-2031)
    • 日本の治療のためのRNAi 市場規模および予測 (2020-2031)
    • オーストラリア 治療のためのRNAi 市場規模および予測 (2020-2031)

第3章 内訳データ：タイプ別

  • 世界の治療のためのRNAiの市場規模実績：タイプ別 (2020-2025)
  • 世界の治療のためのRNAiの市場規模予測：タイプ別 (2026-2031)
  • 各種タイプ 治療のためのRNAi 代表的な企業

第4章 内訳データ：用途別

  • 世界の治療のためのRNAiの市場規模実績：用途別 (2020-2025)
  • 世界の治療のためのRNAiの市場規模予測：用途別 (2026-2031)
  • 新たな成長源 治療のためのRNAi アプリケーション

第5章 競合他社の状況

  • 世界トップ企業 収益
    • 世界の治療のためのRNAiの上位企業：収益別 (2020-2025)
    • 世界の治療のためのRNAiの収益シェア：企業別 (2020-2025)
  • 世界の企業タイプ別市場シェア (Tier 1, Tier 2, and Tier 3)
  • 企業ランキング： 治療のためのRNAi 収益
  • 世界の治療のためのRNAi 市場集中度分析
    • 世界の治療のためのRNAi 市場集中度 (CR5 and HHI)
    • 世界の上位10・上位5企業： 治療のためのRNAi 収益 2024年
  • 世界の主要企業 治療のためのRNAi 本社 および提供地域
  • 世界の主要企業 治療のためのRNAi, 製品およびアプリケーション
  • 世界の主要企業 治療のためのRNAi, 業界参入時期
  • M&A, 拡張計画

第6章 地域分析

  • 北米の市場: Pレイヤー, セグメントs and 下流
    • 北米の治療のためのRNAi 企業別収益 (2020-2025)
    • 北米の市場規模：タイプ別
    • 北米の市場規模：用途別
    • 北米の市場 トレンドと機会
  • 欧州の市場: Pレイヤー, セグメントs and 下流
    • 欧州の治療のためのRNAi 企業別収益 (2020-2025)
    • 欧州の市場規模：タイプ別
    • 欧州の市場規模：用途別
    • 欧州の市場 トレンドと機会
  • 中国の市場: Pレイヤー, セグメントs and 下流
    • 中国の治療のためのRNAi 企業別収益 (2020-2025)
    • 中国の市場規模：タイプ別
    • 中国の市場規模：用途別
    • 中国の市場 トレンドと機会
  • 日本の市場: Pレイヤー, セグメントs and 下流
    • 日本の治療のためのRNAi 企業別収益 (2020-2025)
    • 日本の市場規模：タイプ別
    • 日本の市場規模：用途別
    • 日本の市場 トレンドと機会
  • オーストラリア 市場: Pレイヤー, セグメントs and 下流
    • オーストラリア 治療のためのRNAi 企業別収益 (2020-2025)
    • オーストラリア 市場規模：タイプ別
    • オーストラリア 市場規模：用途別
    • オーストラリア 市場 トレンドと機会

第7章 主要企業のプロファイル

  • Alnylam Pharmaceuticals
  • Arrowhead Pharmaceuticals
  • Arrowhead
  • Silence Therapeutics
  • Benitec Biopharma
  • Phio Pharmaceuticals
  • RXi Pharmaceuticals
  • Arrakis Therapeutics
  • Benitec Biopharma
  • miRagen Therapeutics
  • Sylentis
  • Gradalis
  • Sirnaomics
  • Silenseed

第8章 治療のためのRNAi 市場動向

  • 治療のためのRNAi 業界動向
  • 治療のためのRNAi 市場の促進要因
  • 治療のためのRNAi 市場の課題
  • 治療のためのRNAi 市場の抑制要因

第9章 市場調査結果と結論

第10章 付録

図表

List of Tables

Table 1. Global RNAi for Therapeutic Market Size Growth Rate by Type (US$ Million): 2020 VS 2024 VS 2031

Table 2. Global RNAi for Therapeutic Market Size Growth by Application (US$ Million): 2020 VS 2024 VS 2031

Table 3. Global Market RNAi for Therapeutic Market Size (US$ Million) by Region:2020 VS 2024 VS 2031

Table 4. Global RNAi for Therapeutic Revenue (US$ Million) Market Share by Region (2020-2025)

Table 5. Global RNAi for Therapeutic Revenue Share by Region (2020-2025)

Table 6. Global RNAi for Therapeutic Revenue (US$ Million) Forecast by Region (2026-2031)

Table 7. Global RNAi for Therapeutic Revenue Share Forecast by Region (2026-2031)

Table 8. Global RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 9. Global RNAi for Therapeutic Revenue Market Share by Type (2020-2025)

Table 10. Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031) & (US$ Million)

Table 11. Global RNAi for Therapeutic Revenue Market Share by Type (2026-2031)

Table 12. Representative Players of Each Type

Table 13. Global RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 14. Global RNAi for Therapeutic Revenue Market Share by Application (2020-2025)

Table 15. Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031) & (US$ Million)

Table 16. Global RNAi for Therapeutic Revenue Market Share by Application (2026-2031)

Table 17. New Sources of Growth in RNAi for Therapeutic Application

Table 18. Global RNAi for Therapeutic Revenue by Players (2020-2025) & (US$ Million)

Table 19. Global RNAi for Therapeutic Market Share by Players (2020-2025)

Table 20. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)

Table 21. Ranking of Global Top RNAi for Therapeutic Companies by Revenue (US$ Million) in 2024

Table 22. Global 5 Largest Players Market Share by RNAi for Therapeutic Revenue (CR5 and HHI) & (2020-2025)

Table 23. Global Key Players of RNAi for Therapeutic, Headquarters and Area Served

Table 24. Global Key Players of RNAi for Therapeutic, Product and Application

Table 25. Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry

Table 26. Mergers & Acquisitions, Expansion Plans

Table 27. North America RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 28. North America RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 29. North America RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 30. North America RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 31. Europe RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 32. Europe RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 33. Europe RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 34. Europe RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 35. China RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 36. China RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 37. China RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 38. China RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 39. Japan RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 40. Japan RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 41. Japan RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 42. Japan RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 43. Australia RNAi for Therapeutic Revenue by Company (2020-2025) & (US$ Million)

Table 44. Australia RNAi for Therapeutic Revenue Market Share by Company (2020-2025)

Table 45. Australia RNAi for Therapeutic Market Size by Type (2020-2025) & (US$ Million)

Table 46. Australia RNAi for Therapeutic Market Size by Application (2020-2025) & (US$ Million)

Table 47. Alnylam Pharmaceuticals Company Details

Table 48. Alnylam Pharmaceuticals Business Overview

Table 49. Alnylam Pharmaceuticals RNAi for Therapeutic Product

Table 50. Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 51. Alnylam Pharmaceuticals Recent Development

Table 52. Arrowhead Pharmaceuticals Company Details

Table 53. Arrowhead Pharmaceuticals Business Overview

Table 54. Arrowhead Pharmaceuticals RNAi for Therapeutic Product

Table 55. Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 56. Arrowhead Pharmaceuticals Recent Development

Table 57. Arrowhead Company Details

Table 58. Arrowhead Business Overview

Table 59. Arrowhead RNAi for Therapeutic Product

Table 60. Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 61. Arrowhead Recent Development

Table 62. Silence Therapeutics Company Details

Table 63. Silence Therapeutics Business Overview

Table 64. Silence Therapeutics RNAi for Therapeutic Product

Table 65. Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 66. Silence Therapeutics Recent Development

Table 67. Benitec Biopharma Company Details

Table 68. Benitec Biopharma Business Overview

Table 69. Benitec Biopharma RNAi for Therapeutic Product

Table 70. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 71. Benitec Biopharma Recent Development

Table 72. Phio Pharmaceuticals Company Details

Table 73. Phio Pharmaceuticals Business Overview

Table 74. Phio Pharmaceuticals RNAi for Therapeutic Product

Table 75. Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 76. Phio Pharmaceuticals Recent Development

Table 77. RXi Pharmaceuticals Company Details

Table 78. RXi Pharmaceuticals Business Overview

Table 79. RXi Pharmaceuticals RNAi for Therapeutic Product

Table 80. RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 81. RXi Pharmaceuticals Recent Development

Table 82. Arrakis Therapeutics Company Details

Table 83. Arrakis Therapeutics Business Overview

Table 84. Arrakis Therapeutics RNAi for Therapeutic Product

Table 85. Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 86. Arrakis Therapeutics Recent Development

Table 87. Benitec Biopharma Company Details

Table 88. Benitec Biopharma Business Overview

Table 89. Benitec Biopharma RNAi for Therapeutic Product

Table 90. Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 91. Benitec Biopharma Recent Development

Table 92. miRagen Therapeutics Company Details

Table 93. miRagen Therapeutics Business Overview

Table 94. miRagen Therapeutics RNAi for Therapeutic Product

Table 95. miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 96. miRagen Therapeutics Recent Development

Table 97. Sylentis Company Details

Table 98. Sylentis Business Overview

Table 99. Sylentis RNAi for Therapeutic Product

Table 100. Sylentis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 101. Sylentis Recent Development

Table 102. Gradalis Company Details

Table 103. Gradalis Business Overview

Table 104. Gradalis RNAi for Therapeutic Product

Table 105. Gradalis Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 106. Gradalis Recent Development

Table 107. Sirnaomics Company Details

Table 108. Sirnaomics Business Overview

Table 109. Sirnaomics RNAi for Therapeutic Product

Table 110. Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 111. Sirnaomics Recent Development

Table 112. Silenseed Company Details

Table 113. Silenseed Business Overview

Table 114. Silenseed RNAi for Therapeutic Product

Table 115. Silenseed Revenue in RNAi for Therapeutic Business (2020-2025) & (US$ Million)

Table 116. Silenseed Recent Development

Table 117. RNAi for Therapeutic Market Trends

Table 118. RNAi for Therapeutic Market Drivers

Table 119. RNAi for Therapeutic Market Challenges

Table 120. RNAi for Therapeutic Market Restraints

Table 121. Research Programs/Design for This Report

Table 122. Key Data Information from Secondary Sources

Table 123. Key Data Information from Primary Sources

List of Figures

Figure 1. RNAi for Therapeutic Product Picture

Figure 2. Global RNAi for Therapeutic Market Share by Type: 2024 VS 2031

Figure 3. siRNA Features

Figure 4. miRNA Features

Figure 5. shRNA Features

Figure 6. Global RNAi for Therapeutic Market Share by Application: 2024 VS 2031

Figure 7. Cancer

Figure 8. Cardiovascular

Figure 9. HBV

Figure 10. Others

Figure 11. RNAi for Therapeutic Report Years Considered

Figure 12. Global RNAi for Therapeutic Market Size (US$ Million), Year-over-Year: 2020-2031

Figure 13. Global RNAi for Therapeutic Market Size, (US$ Million), 2020 VS 2024 VS 2031

Figure 14. Global RNAi for Therapeutic Revenue Market Share by Region: 2020 VS 2024

Figure 15. North America RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)

Figure 16. Europe RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)

Figure 17. China RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)

Figure 18. Japan RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)

Figure 19. Australia RNAi for Therapeutic Revenue (US$ Million) Growth Rate (2020-2031)

Figure 20. Global RNAi for Therapeutic Market Share by Players in 2024

Figure 21. Global Top RNAi for Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in RNAi for Therapeutic as of 2024)

Figure 22. The Top 10 and 5 Players Market Share by RNAi for Therapeutic Revenue in 2024

Figure 23. North America RNAi for Therapeutic Market Share by Type (2020-2025)

Figure 24. North America RNAi for Therapeutic Market Share by Application (2020-2025)

Figure 25. Europe RNAi for Therapeutic Market Share by Type (2020-2025)

Figure 26. Europe RNAi for Therapeutic Market Share by Application (2020-2025)

Figure 27. China RNAi for Therapeutic Market Share by Type (2020-2025)

Figure 28. China RNAi for Therapeutic Market Share by Application (2020-2025)

Figure 29. Japan RNAi for Therapeutic Market Share by Type (2020-2025)

Figure 30. Japan RNAi for Therapeutic Market Share by Application (2020-2025)

Figure 31. Australia RNAi for Therapeutic Market Share by Type (2020-2025)

Figure 32. Australia RNAi for Therapeutic Market Share by Application (2020-2025)

Figure 33. Alnylam Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 34. Arrowhead Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 35. Arrowhead Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 36. Silence Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 37. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 38. Phio Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 39. RXi Pharmaceuticals Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 40. Arrakis Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 41. Benitec Biopharma Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 42. miRagen Therapeutics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 43. Sylentis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 44. Gradalis Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 45. Sirnaomics Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 46. Silenseed Revenue Growth Rate in RNAi for Therapeutic Business (2020-2025)

Figure 47. Bottom-up and Top-down Approaches for This Report

Figure 48. Data Triangulation

Figure 49. Key Executives Interviewed

目次

This research report focuses on the RNAi for Therapeutic Market. It analyzes market size, trends and demand forecasts, as well as growth factors and challenges. The report provides market data breakdowns by type, application, company, and region, in addition to competitive landscape and key company profiles.

TABLE OF CONTENTS

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market by Type
    • 1.2.1 Global Market Size Growth by Type: 2020 VS 2024 VS 2031
    • 1.2.2 siRNA
    • 1.2.3 miRNA
    • 1.2.4 shRNA
  • 1.3 Market by Application
    • 1.3.1 Global Market Share by Application: 2020 VS 2024 VS 2031
    • 1.3.2 Cancer
    • 1.3.3 Cardiovascular
    • 1.3.4 HBV
    • 1.3.5 Others
  • 1.4 Assumptions and Limitations
  • 1.5 Study Objectives
  • 1.6 Years Considered

2 Global Growth Trends

  • 2.1 Global RNAi for Therapeutic Market Perspective (2020-2031)
  • 2.2 Global Market Size by Region: 2020 VS 2024 VS 2031
  • 2.3 Global RNAi for Therapeutic Revenue Market Share by Region (2020-2025)
  • 2.4 Global RNAi for Therapeutic Revenue Forecast by Region (2026-2031)
  • 2.5 Major Region and Emerging Market Analysis
    • 2.5.1 North America RNAi for Therapeutic Market Size and Prospective (2020-2031)
    • 2.5.2 Europe RNAi for Therapeutic Market Size and Prospective (2020-2031)
    • 2.5.3 China RNAi for Therapeutic Market Size and Prospective (2020-2031)
    • 2.5.4 Japan RNAi for Therapeutic Market Size and Prospective (2020-2031)
    • 2.5.5 Australia RNAi for Therapeutic Market Size and Prospective (2020-2031)

3 Breakdown Data by Type

  • 3.1 Global RNAi for Therapeutic Historic Market Size by Type (2020-2025)
  • 3.2 Global RNAi for Therapeutic Forecasted Market Size by Type (2026-2031)
  • 3.3 Different Types RNAi for Therapeutic Representative Players

4 Breakdown Data by Application

  • 4.1 Global RNAi for Therapeutic Historic Market Size by Application (2020-2025)
  • 4.2 Global RNAi for Therapeutic Forecasted Market Size by Application (2026-2031)
  • 4.3 New Sources of Growth in RNAi for Therapeutic Application

5 Competition Landscape by Players

  • 5.1 Global Top Players by Revenue
    • 5.1.1 Global Top RNAi for Therapeutic Players by Revenue (2020-2025)
    • 5.1.2 Global RNAi for Therapeutic Revenue Market Share by Players (2020-2025)
  • 5.2 Global Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
  • 5.3 Players Covered: Ranking by RNAi for Therapeutic Revenue
  • 5.4 Global RNAi for Therapeutic Market Concentration Analysis
    • 5.4.1 Global RNAi for Therapeutic Market Concentration Ratio (CR5 and HHI)
    • 5.4.2 Global Top 10 and Top 5 Companies by RNAi for Therapeutic Revenue in 2024
  • 5.5 Global Key Players of RNAi for Therapeutic Head office and Area Served
  • 5.6 Global Key Players of RNAi for Therapeutic, Product and Application
  • 5.7 Global Key Players of RNAi for Therapeutic, Date of Enter into This Industry
  • 5.8 Mergers & Acquisitions, Expansion Plans

6 Region Analysis

  • 6.1 North America Market: Players, Segments and Downstream
    • 6.1.1 North America RNAi for Therapeutic Revenue by Company (2020-2025)
    • 6.1.2 North America Market Size by Type
      • 6.1.2.1 North America RNAi for Therapeutic Market Size by Type (2020-2025)
      • 6.1.2.2 North America RNAi for Therapeutic Market Share by Type (2020-2025)
    • 6.1.3 North America Market Size by Application
      • 6.1.3.1 North America RNAi for Therapeutic Market Size by Application (2020-2025)
      • 6.1.3.2 North America RNAi for Therapeutic Market Share by Application (2020-2025)
    • 6.1.4 North America Market Trend and Opportunities
  • 6.2 Europe Market: Players, Segments and Downstream
    • 6.2.1 Europe RNAi for Therapeutic Revenue by Company (2020-2025)
    • 6.2.2 Europe Market Size by Type
      • 6.2.2.1 Europe RNAi for Therapeutic Market Size by Type (2020-2025)
      • 6.2.2.2 Europe RNAi for Therapeutic Market Share by Type (2020-2025)
    • 6.2.3 Europe Market Size by Application
      • 6.2.3.1 Europe RNAi for Therapeutic Market Size by Application (2020-2025)
      • 6.2.3.2 Europe RNAi for Therapeutic Market Share by Application (2020-2025)
    • 6.2.4 Europe Market Trend and Opportunities
  • 6.3 China Market: Players, Segments and Downstream
    • 6.3.1 China RNAi for Therapeutic Revenue by Company (2020-2025)
    • 6.3.2 China Market Size by Type
      • 6.3.2.1 China RNAi for Therapeutic Market Size by Type (2020-2025)
      • 6.3.2.2 China RNAi for Therapeutic Market Share by Type (2020-2025)
    • 6.3.3 China Market Size by Application
      • 6.3.3.1 China RNAi for Therapeutic Market Size by Application (2020-2025)
      • 6.3.3.2 China RNAi for Therapeutic Market Share by Application (2020-2025)
    • 6.3.4 China Market Trend and Opportunities
  • 6.4 Japan Market: Players, Segments and Downstream
    • 6.4.1 Japan RNAi for Therapeutic Revenue by Company (2020-2025)
    • 6.4.2 Japan Market Size by Type
      • 6.4.2.1 Japan RNAi for Therapeutic Market Size by Type (2020-2025)
      • 6.4.2.2 Japan RNAi for Therapeutic Market Share by Type (2020-2025)
    • 6.4.3 Japan Market Size by Application
      • 6.4.3.1 Japan RNAi for Therapeutic Market Size by Application (2020-2025)
      • 6.4.3.2 Japan RNAi for Therapeutic Market Share by Application (2020-2025)
    • 6.4.4 Japan Market Trend and Opportunities
  • 6.5 Australia Market: Players, Segments and Downstream
    • 6.5.1 Australia RNAi for Therapeutic Revenue by Company (2020-2025)
    • 6.5.2 Australia Market Size by Type
      • 6.5.2.1 Australia RNAi for Therapeutic Market Size by Type (2020-2025)
      • 6.5.2.2 Australia RNAi for Therapeutic Market Share by Type (2020-2025)
    • 6.5.3 Australia Market Size by Application
      • 6.5.3.1 Australia RNAi for Therapeutic Market Size by Application (2020-2025)
      • 6.5.3.2 Australia RNAi for Therapeutic Market Share by Application (2020-2025)
    • 6.5.4 Australia Market Trend and Opportunities

7 Key Players Profiles

  • 7.1 Alnylam Pharmaceuticals
    • 7.1.1 Alnylam Pharmaceuticals Company Details
    • 7.1.2 Alnylam Pharmaceuticals Business Overview
    • 7.1.3 Alnylam Pharmaceuticals RNAi for Therapeutic Introduction
    • 7.1.4 Alnylam Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.1.5 Alnylam Pharmaceuticals Recent Development
  • 7.2 Arrowhead Pharmaceuticals
    • 7.2.1 Arrowhead Pharmaceuticals Company Details
    • 7.2.2 Arrowhead Pharmaceuticals Business Overview
    • 7.2.3 Arrowhead Pharmaceuticals RNAi for Therapeutic Introduction
    • 7.2.4 Arrowhead Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.2.5 Arrowhead Pharmaceuticals Recent Development
  • 7.3 Arrowhead
    • 7.3.1 Arrowhead Company Details
    • 7.3.2 Arrowhead Business Overview
    • 7.3.3 Arrowhead RNAi for Therapeutic Introduction
    • 7.3.4 Arrowhead Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.3.5 Arrowhead Recent Development
  • 7.4 Silence Therapeutics
    • 7.4.1 Silence Therapeutics Company Details
    • 7.4.2 Silence Therapeutics Business Overview
    • 7.4.3 Silence Therapeutics RNAi for Therapeutic Introduction
    • 7.4.4 Silence Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.4.5 Silence Therapeutics Recent Development
  • 7.5 Benitec Biopharma
    • 7.5.1 Benitec Biopharma Company Details
    • 7.5.2 Benitec Biopharma Business Overview
    • 7.5.3 Benitec Biopharma RNAi for Therapeutic Introduction
    • 7.5.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.5.5 Benitec Biopharma Recent Development
  • 7.6 Phio Pharmaceuticals
    • 7.6.1 Phio Pharmaceuticals Company Details
    • 7.6.2 Phio Pharmaceuticals Business Overview
    • 7.6.3 Phio Pharmaceuticals RNAi for Therapeutic Introduction
    • 7.6.4 Phio Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.6.5 Phio Pharmaceuticals Recent Development
  • 7.7 RXi Pharmaceuticals
    • 7.7.1 RXi Pharmaceuticals Company Details
    • 7.7.2 RXi Pharmaceuticals Business Overview
    • 7.7.3 RXi Pharmaceuticals RNAi for Therapeutic Introduction
    • 7.7.4 RXi Pharmaceuticals Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.7.5 RXi Pharmaceuticals Recent Development
  • 7.8 Arrakis Therapeutics
    • 7.8.1 Arrakis Therapeutics Company Details
    • 7.8.2 Arrakis Therapeutics Business Overview
    • 7.8.3 Arrakis Therapeutics RNAi for Therapeutic Introduction
    • 7.8.4 Arrakis Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.8.5 Arrakis Therapeutics Recent Development
  • 7.9 Benitec Biopharma
    • 7.9.1 Benitec Biopharma Company Details
    • 7.9.2 Benitec Biopharma Business Overview
    • 7.9.3 Benitec Biopharma RNAi for Therapeutic Introduction
    • 7.9.4 Benitec Biopharma Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.9.5 Benitec Biopharma Recent Development
  • 7.10 miRagen Therapeutics
    • 7.10.1 miRagen Therapeutics Company Details
    • 7.10.2 miRagen Therapeutics Business Overview
    • 7.10.3 miRagen Therapeutics RNAi for Therapeutic Introduction
    • 7.10.4 miRagen Therapeutics Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.10.5 miRagen Therapeutics Recent Development
  • 7.11 Sylentis
    • 7.11.1 Sylentis Company Details
    • 7.11.2 Sylentis Business Overview
    • 7.11.3 Sylentis RNAi for Therapeutic Introduction
    • 7.11.4 Sylentis Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.11.5 Sylentis Recent Development
  • 7.12 Gradalis
    • 7.12.1 Gradalis Company Details
    • 7.12.2 Gradalis Business Overview
    • 7.12.3 Gradalis RNAi for Therapeutic Introduction
    • 7.12.4 Gradalis Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.12.5 Gradalis Recent Development
  • 7.13 Sirnaomics
    • 7.13.1 Sirnaomics Company Details
    • 7.13.2 Sirnaomics Business Overview
    • 7.13.3 Sirnaomics RNAi for Therapeutic Introduction
    • 7.13.4 Sirnaomics Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.13.5 Sirnaomics Recent Development
  • 7.14 Silenseed
    • 7.14.1 Silenseed Company Details
    • 7.14.2 Silenseed Business Overview
    • 7.14.3 Silenseed RNAi for Therapeutic Introduction
    • 7.14.4 Silenseed Revenue in RNAi for Therapeutic Business (2020-2025)
    • 7.14.5 Silenseed Recent Development

8 RNAi for Therapeutic Market Dynamics

  • 8.1 RNAi for Therapeutic Industry Trends
  • 8.2 RNAi for Therapeutic Market Drivers
  • 8.3 RNAi for Therapeutic Market Challenges
  • 8.4 RNAi for Therapeutic Market Restraints

9 Research Findings and Conclusion

10 Appendix

  • 10.1 Research Methodology
    • 10.1.1 Methodology/Research Approach
      • 10.1.1.1 Research Programs/Design
      • 10.1.1.2 Market Size Estimation
      • 10.1.1.3 Market Breakdown and Data Triangulation
    • 10.1.2 Data Source
      • 10.1.2.1 Secondary Sources
      • 10.1.2.2 Primary Sources
  • 10.2 Author Details
  • 10.3 Disclaimer